In the past week, IMVT stock has gone down by -3.19%, with a monthly decline of -10.96% and a quarterly plunge of -29.11%. The volatility ratio for the week is 10.21%, and the volatility levels for the last 30 days are 6.53% for Immunovant Inc The simple moving average for the last 20 days is -6.43% for IMVT stock, with a simple moving average of -31.44% for the last 200 days.
Is It Worth Investing in Immunovant Inc (NASDAQ: IMVT) Right Now?
Moreover, the 36-month beta value for IMVT is 0.75. Analysts have varying opinions on the stock, with 10 analysts rating it as a “buy,” 3 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for IMVT is 69.37M and currently, short sellers hold a 22.19% of that float. On March 26, 2025, IMVT’s average trading volume was 1.42M shares.
IMVT) stock’s latest price update
Immunovant Inc (NASDAQ: IMVT) has seen a decline in its stock price by -6.43 in relation to its previous close of 19.44. However, the company has experienced a -3.19% decline in its stock price over the last five trading sessions. zacks.com reported 2025-03-20 that Immunovant’s batoclimab shows strong efficacy in MG & CIDP, but shifts focus to the lead drug IMVT-1402 for these indications to induce deeper, lasting relief.
Analysts’ Opinion of IMVT
Many brokerage firms have already submitted their reports for IMVT stocks, with Jefferies repeating the rating for IMVT by listing it as a “Hold.” The predicted price for IMVT in the upcoming period, according to Jefferies is $20 based on the research report published on March 03, 2025 of the current year 2025.
Raymond James gave a rating of “Outperform” to IMVT, setting the target price at $36 in the report published on October 10th of the previous year.
IMVT Trading at -12.26% from the 50-Day Moving Average
After a stumble in the market that brought IMVT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.23% of loss for the given period.
Volatility was left at 6.53%, however, over the last 30 days, the volatility rate increased by 10.21%, as shares sank -8.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.53% lower at present.
During the last 5 trading sessions, IMVT fell by -3.19%, which changed the moving average for the period of 200-days by -28.95% in comparison to the 20-day moving average, which settled at $19.44. In addition, Immunovant Inc saw -26.56% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMVT starting from Fromkin Andrew J., who sale 8,000 shares at the price of $19.60 back on Mar 07 ’25. After this action, Fromkin Andrew J. now owns 91,913 shares of Immunovant Inc, valued at $156,769 using the latest closing price.
ANDREW J FROMKIN, the Director of Immunovant Inc, proposed sale 8,000 shares at $19.52 during a trade that took place back on Mar 07 ’25, which means that ANDREW J FROMKIN is holding shares at $156,160 based on the most recent closing price.
Stock Fundamentals for IMVT
Current profitability levels for the company are sitting at:
- -270.14 for the present operating margin
- 0.9 for the gross margin
The net margin for Immunovant Inc stands at -255.14. The total capital return value is set at -1.15. Equity return is now at value -74.17, with -67.59 for asset returns.
Based on Immunovant Inc (IMVT), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -14127.65.
Currently, EBITDA for the company is -269.98 million with net debt to EBITDA at 0.93. When we switch over and look at the enterprise to sales, we see a ratio of 1810.07. The receivables turnover for the company is 0.67for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.04.
Conclusion
To wrap up, the performance of Immunovant Inc (IMVT) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
